secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001171843-24-006247
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M
----------------------------------------------------------------------

- Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.
- Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.
- Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.
- CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.
- CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/0001171843-24-006247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/f8k_111224.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer